Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway.
In July 2006, the seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in Norway with a reduced (2 doses + 1 boost) dose schedule. Post-PCV7 shifts in pneumococcal reservoirs were assessed by two point prevalence studies of nasopharyngeal colonization among children in day care centers, before (2006) and after (2008) widespread use of PCV7. Nasopharyngeal swabs were obtained from 1,213 children, 611 in 2006 and 602 in 2008. A total of 1,102 pneumococcal isolates were recovered. Serotyping, multilocus sequence typing, and antimicrobial drug susceptibility testing were performed on all isolates. Although carriage of PCV7 serotypes decreased among both vaccinated and unvaccinated children, the overall prevalence of pneumococcal carriage remained high (80.4%) after vaccine introduction. The pneumococcal populations were diverse, and in the shift toward non-PCV7 serotypes, expansion of a limited number of established clonal complexes was observed. While non-antimicrobial-susceptible clones persisted among PCV7 serotypes, antimicrobial resistance did not increase among non-PCV7 serotypes. Direct and indirect protection of PCV7 against nasopharyngeal colonization was inferred from an overall decrease in carriage of PCV7 serotypes. No preference was found for nonsusceptible clones among the replacing non-PCV7 serotypes.
Vestrheim
Didrik F
DF
Department of Bacteriology and Immunology, Division of Infectious Disease Control, Norwegian Institute of Public Health, Nydalen, Oslo, Norway.
Høiby
E Arne
EA
Aaberge
Ingeborg S
IS
Caugant
Dominique A
DA
D002353:Carrier State / Q000453:epidemiology*; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D024881:Drug Resistance, Bacterial; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009297:Nasal Mucosa / Q000382:microbiology*; D009664:Norway / Q000453:epidemiology; D011008:Pneumococcal Infections / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000276:immunology*; D015995:Prevalence; D013296:Streptococcus pneumoniae / Q000145:classification / Q000302:isolation & purification; D018074:Vaccines, Conjugate
D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate